1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. GLENMARK PHARMACEUTICALS LTD.
Glenmark Pharmaceuticals Ltd.
NSE: GLENMARK | BSE: 532296

Glenmark Pharma Live Share Price Today, Share Analysis and Chart

Strong Performer, Getting Expensive
BasketIn 2 Starfolio Baskets
aboutGlenmark Pharmaceuticals Ltd. is a global research-led pharmaceutical company based in India. It maintains a strong commercial presence across more than 80 countries, with significant operations in India, North America, Europe, and emerging markets. ... Read More
Ask AI about Glenmark Pharma
2408.0026.00(1.09%)

33.67% Gain from 52W Low

949.1K
NSE+BSE Volume

NSE 03 Nov, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Glenmark Pharma is on 05 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
64.2 / 100
Strong Performer, Getting ExpensiveThese stocks are strong in quality and technicals but have medium valuation. At somewhat expensive valuations, investors should be cautious before buyingView SimilarEmbed DVM
Analyst Price Target
-

34

S

1

W

5

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

16Positive7Negative

Pass in checklist69.6%

045
55
100

PE Valuation Check

Right Now
Undervalued
65.3%
1 Year Forward
Undervalued
104.4%
INSIGHTGlenmark Pharma is undervalued at both current PE and future earnings estimates.

Glenmark Pharma Stock Price Analysis

Day Price Range

1.1% 1 Day return
2408 (LTP)
2,360.12,420
LowHigh

Week Price Range

8.2% 1 Week return
2408 (LTP)
2,214.62,420
LowHigh

Month Price Range

3.3% 1 Month return
2408 (LTP)
2,101.62,420
LowHigh

52 Week Price Range

27.3% 1 Year return
2408 (LTP)
1,801.42,537.6
LowHigh
View full Price History/Seasonality

Glenmark Pharma Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Miss

Glenmark Pharma's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
48.2
AVG. ESTIMATE
82
LOW ESTIMATE
73
HIGH ESTIMATE
87.6
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 69.9% in FY27

Consensus Recommendation

12 ANALYST Recommendations
BUY

The consensus recommendation from 12 analysts for Glenmark Pharma is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Glenmark Pharma Technical Analysis

Glenmark Pharma EMA & SMA

Bullish+8
8 bullish, 0 bearish
Bullish8
Bearish0
5 Day2348.3
10 Day2311.2
12 Day2304.8
20 Day2299.9
26 Day2303.8
50 Day2313.6
100 Day2295.5
200 Day2216.2

Glenmark Pharma Delivery And Volume

Daily Avg. Delivery Volume %
03 Nov, 202650.9%
Week48.4%
Month50.6%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Glenmark Pharma Resistance and Support

2396.03
Pivot
First Resistance2432.0
Second Resistance2455.9
Third Resistance2491.9
First Support2372.1
Second Support2336.1
Third Support2312.2
Day RSI60.9
Day MACD1
Day MFI59
Day MACD Signal Line-23

Glenmark Pharma Beta

1 Month1.2
1 Year0.9
3 Month1
3 Year0.8

Glenmark Pharma Price Change Analysis

↑3.3%
Over 1 Month
LowHigh
2101.62420
↑7.8%
Over 3 Months
LowHigh
2101.62537.6
↑0.1%
Over 6 Months
LowHigh
21012537.6
↑27.3%
Over 1 Year
LowHigh
1801.42537.6
All Technicals →

Glenmark Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Saldanha Family TrustPromoter128,241,93645.4 %
Government Pension Fund GlobalFii10,815,9813.8 %
Hdfc Mutual Fund - Hdfc Manufacturing FundDii16,953,5946.0 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Glenmark Pharma Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
GRAVITON RESEARCH CAPITAL LLPBulkSell11 Jul 20252173.311,510,591NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase11 Jul 20252171.671,510,591NSE
UBS AGBlockSell25 Mar 20251492.65264,465NSE
INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.BlockPurchase25 Mar 20251492.65264,465NSE
UBS PRINCIPAL CAPITAL ASIA LIMITEDBlockSell23 Jan 20251510671,394NSE
UBS AGBlockPurchase23 Jan 20251510671,394NSE
ISHARES INDIA SC MAURITIUS COMPANYBlockSell25 Oct 2022397.9039,265BSE
ISHARES CORE EMERGING MARKETS MAURITIUS COBlockSell25 Oct 2022397.90302,621BSE
ISHARES MSCI INDIA SMALL-CAP ETFBlockPurchase25 Oct 2022397.9039,265BSE
ISHARES CORE MSCI EMERGING MARKETS ETFBlockPurchase25 Oct 2022397.90302,621BSE
All deals
All insider trades

Glenmark Pharma Corporate Actions

Glenmark Pharma Dividend history and yield

Glenmark Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Glenmark Pharma dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
131 Aug 2026
2.5FINAL31 Aug 2026Equity Share
203 Oct 2025
2.5INTERIM03 Oct 2025Equity Share
315 Sep 2025
2.5FINAL15 Sep 2025Equity Share
413 Sep 2024
2.5FINAL-Equity Share
518 Sep 2023
2.5FINAL-Equity Share

Glenmark Pharma Bonus shares

Glenmark Pharma bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
104 Mar 2005
1:1-

Glenmark Pharma Board Meetings

Glenmark Pharma past and upcoming board meetings.

#Ex-Date
PurposeNotes
105 Nov 2026
Quarterly Results-
231 Jul 2026
Quarterly Results-
329 May 2026
Audited Results & Final Dividend-
430 Jan 2026
Quarterly Results-
514 Nov 2025
Quarterly Results-

Glenmark Pharma Stock Split

Glenmark Pharma stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
110 Sep 2007
21-
223 Oct 2003
10231 Oct 2003
All Corporate Actions

Glenmark Pharma Research Reports

Glenmark Pharma research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
106 Aug 2026Deven Choksey
Target
25632270Accumulate12.91%6.08%pdf
203 Aug 2026ICICI Securities Limited
Reco
Target
21002225Hold-5.62%8.22%pdf
302 Aug 2026Motilal Oswal25702230Buy15.25%7.98%pdf
408 Jul 2026Deven Choksey24102267.2Accumulate6.3%6.21%pdf
530 Jun 2026Geojit BNP Paribas
Target
25052161.9Accumulate15.87%11.38%pdf
All Reports of Glenmark

Glenmark Pharma Corporate Filings

Glenmark Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
23 Oct 2026
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Intimation of Earnings Call
PDF
23 Oct 2026
Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results Of Glenmark Pharmaceuticals Limited ('The Company') For The Quarter And Half Year Ended September 30, 2026
Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026
PDF
06 Oct 2026
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Therapeutics Inc. USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)
PDF
28 Sep 2026
Glenmark Pharmaceuticals Ltd - 532296 - Closure of Trading Window
Intimation for closure of trading window for second quarter of FY 2026-27
PDF
23 Sep 2026
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives Establishment Inspection Report (EIS) from U.S. FDA for its Goa facility with VAI classification
PDF
VIEW ALL

Glenmark Pharma DocumentsAsk MarketMind AI

Glenmark Pharma Earnings Call

Glenmark Pharma earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
05 Aug 2026Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
03 Aug 2026Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
03 Aug 2026Glenmark Pharmaceuticals Results Earnings Call for Q1FY27AudioVideo
05 Jun 2026Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
04 Feb 2026Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
view all

Glenmark Pharma Annual Reports

Glenmark Pharma financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Glenmark Pharma Credit Ratings

Glenmark Pharma credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
09 Sep 2026india ratingsIndia Ratings Upgrades Glenmark Pharmaceuticals’ Bank Loans to ‘IND AA+’/Stable; Rates Additional LoansLink
11 Aug 2026crisil ratingsGlenmark Pharmaceuticals LimitedGlenmark Pharmaceuticals Limited:Update on Glenmark Pharmaceuticals LimitedLink
10 Feb 2026crisil ratingsGlenmark Pharmaceuticals LimitedGlenmark Pharmaceuticals Limited:Update on Glenmark Pharmaceuticals LimitedLink
17 Sep 2025crisil ratingsGlenmark Pharmaceuticals LimitedGlenmark Pharmaceuticals Limited:Rating outlook revised to 'Positive'; Ratings ReaffirmedLink
22 Jul 2025india ratingsIndia Ratings Revises Outlook on Glenmark Pharmaceuticals’s Long-term Bank Facilities to Positive; Affirms at 'IND AA’Link

Glenmark Pharma Investor Presentations

Glenmark Pharma investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
31 Jul 2026Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
09 Jun 2026Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
29 May 2026Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
30 Jan 2026Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
14 Nov 2025Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Glenmark Pharma - Company Profile

Glenmark Pharma Management Structure

Glenmark Pharma management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Anurag MantriExecutive Director,Global Chief Financial Officer972.1Mar 26
Mr. Alind SharmaPresident,Chief Human Resources Officer-Mar 26
Mr. Alok MalikPresident,Business Head(India Formulations)-Mar 26
Mr. Ulhas DhuppadPresident,Head(Global Pharmaceutical Development)-Mar 26
Mr. Indrajit BosePresident,Chief Quality Officer-Mar 26
Mr. Brijlal MotwaniPresident,Chief Quality Officer-Mar 26
Mr. Samir KaziExecutive Vice President,Head(Legal.,Compliance,IP Services)-Mar 26
Rashmi Khandelwal.Company Secretary,Compliance Officer-Mar 26

Glenmark Pharma Board of Directors

Glenmark Pharma Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Glenn SaldanhaChairman / Executive Director / M D / Promoter1922Mar 26
Anurag MantriExecutive Director & Group CFO972.1Mar 26
Cheryl PintoExecutive Director (Corporate)654Mar 26
V R IyerIndependent Non Exe. Director32Mar 26
Pradeep Kumar SinhaIndependent Non Exe. Director21Mar 26
Dipankar BhattacharjeeIndependent Non Exe. Director19Mar 26
Sona Saira RamasastryIndependent Non Exe. Director18Mar 26
Patricia AndrewsIndependent Non Exe. Director10Mar 26
B E SaldanhaNon Executive Director6Mar 26
Rashmi Khandelwal.Company Secretary / Compliance Officer-Mar 26

Glenmark Pharma Brands

Brands owned by Glenmark Pharma

LOGOBRAND NAME
D Acne Foaming Face Wash
Asar-CT 40/12.5
Airtec FB 200 Instacap
Airtec FB 400 Inhaler
LOGOBRAND NAME
Candiderma Plus
Candidox 1% Cream
Candidox Lotion
Candidox Spray
LOGOBRAND NAME
Glimulin MV2 Forte
Glinate Tablet
Glucar
HALOVATE CREAM
LOGOBRAND NAME
Oxuba
Oxuba OD
Paxyb
Powercort Ointment
Website: www.glenmarkpharma.com

About the company - Business Profile

Glenmark Pharmaceuticals Ltd. is a global research-led pharmaceutical company based in India. It maintains a strong commercial presence across more than 80 countries, with significant operations in India, North America, Europe, and emerging markets. The company operates through an integrated platform comprising 11 manufacturing facilities and 4 research and development (R&D) centers. Glenmark focuses on branded generics, specialty products, and innovative medicines, with core therapeutic expertise in Dermatology, Respiratory, and Oncology.

Key Points

  • Key Facts: Founded in 1977 by Mr. Gracias Saldanha, headquartered in Mumbai, India. The company is listed on the BSE (532296) and NSE (GLENMARK).
  • Operations and Resources: Operates 11 manufacturing sites globally, including major formulation facilities in Goa, Baddi, Indore, Sikkim, Nashik (India), Monroe (USA), Pilar (Argentina), and Vysoke Myto (Czech Republic). It has 4 R&D centers located in Sinnar, Mahape, Taloja (India), and Lausanne (Switzerland).
  • Ownership and Significance: Glenmark is a leading player in the Indian pharmaceutical market, ranking 2nd in Dermatology and Respiratory, and 4th in Cardiac segments. It transitioned into Glenmark 3.0, focusing on a more innovation-led and resilient enterprise.
  • Business Model and Expertise: The company follows a research-led model focused on the entire value chain from API to finished formulations. It excels in developing complex generics and specialty medicines, particularly in the respiratory and dermatology spaces.

Revenue Breakdown (FY 2024-25 Annual)

  • Total Revenue from Operations: INR 133,217 million.
  • Geographical Revenue Contribution:
    • India: 34% (INR 45,293 million).
    • North America: 23% (INR 30,639 million).
    • Emerging Markets (APAC, MEA, RCIS, LATAM): 22% (INR 29,307 million).
    • Europe: 21% (INR 27,978 million).
  • Note: International markets contribute approximately 66% of total revenue.

Key Products and Technology

  • Flagship Products: RYALTRIS® (global respiratory product), WINLEVI® (Dermatology), and Candid Cream (Dermatology).
  • Innovation: Successfully out-licensed 10 deals since 2004. Current innovative assets in clinical development include 1 in Oncology and 2 in Immunology.
  • Recent Launches: Launched the world’s first nebulized fixed-dose triple therapy for COPD in India.
  • Patents: Over 1,343 patents granted as of FY 2025.

Employees and Subsidiaries

  • Employee Count: Approximately 15,800 global employees representing 50+ nationalities.
  • Diversity: 9.9% women in management roles; 44% women on the Board.
  • Major Subsidiaries: Glenmark Pharmaceuticals Inc. (USA), Glenmark Pharmaceuticals Europe Limited.
  • Divestment: Divested a majority stake in Glenmark Life Sciences (GLS) in FY 2024 to strengthen the balance sheet and focus on the branded formulations business.

Strategic Initiatives and Sustainability

  • Glenmark 3.0: A strategic initiative to transform into an innovation-led enterprise with a focus on specialty and innovative assets.
  • Sustainability: Achieved a Bronze medal from EcoVadis for 2024. Invested INR 43 million in energy efficiency and conservation in FY 2025.
  • Financial Outlook: For H2 FY 2025-26, the company guided for estimated revenue of over INR 80,000 million and EBITDA margins of approximately 23%.

References

  1. Annual Report May 2025
  2. Annual Report May 2024
  3. Investor Presentation Jan 2026
  4. Investor Presentation Nov 2025

Glenmark Pharma FAQ

Glenmark Pharma today is trading in the green, up by 1.09% at ₹2,408.
Glenmark Pharma is currently trading up 1.09% on an intraday basis. In the past week the stock rose 8.19%. Stock has been up 7.79% in the past quarter and rose 27.33% in the past year. You can view this in the share price history/seasonality section.
Glenmark Pharma is listed on NSE with the ticker GLENMARK and on BSE as 532296. It's currently trading on NSE at a share price of ₹2,408 and on BSE with a share price of ₹2,405.
The market cap of Glenmark Pharma is ₹67,959.71 Cr. as of Nov 03, 2026.
Glenmark Pharma announced a FINAL dividend of 250% which equals ₹2.5 in Aug 31, 2026.The last three ex-dates for Glenmark Pharma were Oct 03, 2025, Sep 15, 2025 and Sep 13, 2024. To view the full dividend history of Glenmark Pharma click here.
Glenmark Pharma has undergone 2 stock splits and announced bonus shares 1 time since its BSE/NSE listing. The latest announcement for Glenmark Pharma stock split was on Sep 10, 2007 at a ratio of 2:1 and the last bonus share announcement was on Mar 04, 2005 at a ratio of 1:1.
Glenmark Pharma reported ₹4,084.25 Cr. in revenue, ₹482.92 Cr. in net profit, and ₹870.56 Cr. in EBITD as of Jul 31, 2026 for Q1 FY26-27.
According to the predictions of 11 analysts, the share price prediction for Glenmark Pharma is ₹2,512.82 with an upside of 4%.
The PE ratio of Glenmark Pharma is 37.8 as of Nov 03, 2026.
The PB ratio of Glenmark Pharma is 6.18 as of Nov 03, 2026.
You can view the latest analyst reports on the Glenmark Pharma reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×